MariMed Inc. filings document formal disclosures for a cannabis consumer products and retail operator, including annual-meeting governance, operating results and material capital-structure agreements. Recent Form 8-K reports furnish quarterly and annual financial results and describe the restructuring of the company's Series B Convertible Preferred Stock obligation, including related debt and equity components.
Proxy materials disclose stockholder meeting procedures and board-governance matters. The filings also identify MariMed's emerging growth company status and provide public records for transactions, obligations and reporting events connected to its cannabis brand, wholesale distribution and dispensary operations.
MARIMED INC. (MRMD) reported insider equity activity by Chief Operating Officer Timothy Shaw. On 2026-09-01, 65,000 Restricted Stock Units converted on a one-for-one basis into common stock. Of these, 22,523 shares of common stock were withheld at $0.0816 per share to satisfy tax withholding obligations, with the remaining shares effectively delivered to Shaw. Separately, 2,000,000 common shares are reported as held indirectly by the Shaw Family Trust for his children; the trust is irrevocable, Shaw’s spouse is trustee, and Shaw disclaims beneficial ownership of those securities.
MariMed Inc., a U.S. multi-state cannabis operator, reported for the six months ended June 30, 2026 revenue of $81.4 million, up from $77.4 million a year earlier, with three-month revenue of $41.9 million. Retail and wholesale product sales remained the core of the business.
The company generated Adjusted EBITDA of $7.5 million for the first half of 2026 versus $7.3 million in 2025, but recorded a net loss of $7.3 million attributable to common stockholders and higher interest expense and taxes. Total assets were $197.2 million, against $147.1 million of liabilities and $78.8 million of mortgages and notes payable.
MariMed restructured its Series B preferred obligation into $8.0 million of new notes and new Series B preferred shares, recognizing a $0.7 million gain on extinguishment. A Schedule III reclassification of qualifying cannabis activity reduced income tax expense by about $0.8 million, though IRS tax liens of roughly $7 million remain outstanding and disputed.
MariMed Inc. reported second quarter 2026 revenue of $41.9 million, up from $39.5 million a year earlier, driven by growth in both retail and wholesale product sales. GAAP gross margin was 38.7%, with non-GAAP gross margin of 40.0%.
The company recorded a GAAP net loss of $3.6 million for the quarter compared with a loss of $1.4 million in 2025. Non-GAAP net loss was $2.4 million, versus non-GAAP net income of $0.3 million a year earlier. Non-GAAP Adjusted EBITDA was $3.9 million, down from $4.8 million, and the Adjusted EBITDA margin declined to 9.4% from 12.1%.
For the first six months of 2026, revenue was $81.4 million and net cash provided by operating activities increased to $3.2 million from $1.6 million. As of June 30, 2026, MariMed reported total assets of $197.2 million, cash of $8.4 million, total liabilities of $147.1 million, income taxes payable of $31.5 million, mezzanine equity of $6.9 million and stockholders’ equity of $43.2 million.
MARIMED INC. President and CEO Jon R. Levine reported on July 15, 2026 the vesting and settlement of 30,625 restricted stock units into common stock and a related 10,612-share tax-withholding disposition. Following these transactions, he directly holds 21,358,631 common shares, with 91,875 RSUs remaining under the grant that will vest in three equal installments on October 15, 2026, January 15, 2027 and April 15, 2027. An additional 6,684,640 shares are held in a family trust for his spouse and children, for which he disclaims beneficial ownership.
MariMed Inc. reports that COO Timothy Shaw exercised 42,656 RSUs into common stock and had 14,781 shares withheld to satisfy tax obligations related to the vesting. After these transactions, he holds 9,412,123 shares directly and 127,969 RSUs, plus 2,000,000 shares held in an irrevocable family trust for his children, for which he disclaims beneficial ownership.
MARIMED INC. Chief Commercial Officer Ryan Crandall reported RSU vesting and related tax withholding on July 15, 2026. He converted 32,813 Restricted Stock Units into common stock and had 11,370 shares withheld to cover taxes, leaving 1,124,246 common shares and 98,437 RSUs held directly. Remaining RSUs vest in three equal installments through April 15, 2027, and the transactions were not made under a Rule 10b5-1 plan.
MariMed Inc. chief financial officer Mario Pinho reported equity-compensation transactions dated July 15, 2026. He exercised 88,276 restricted stock units into common stock and had 30,589 common shares withheld at $0.0662 per share to satisfy tax withholding obligations. After these transactions, he directly holds 335,172 common shares and continues to hold unvested RSUs from grants dated July 15, 2024 and April 15, 2026 that vest in installments through April 15, 2027.
MARIMED INC. director Eva M.D. Selhub received an equity award of 173,077 Restricted Stock Units on July 15, 2026 as part of her board fees. The RSUs vested immediately and converted one-for-one into 173,077 common shares, after which she directly owns 730,748 common shares.
MARIMED INC. director Allen David R received 192,308 Restricted Stock Units on July 15, 2026 in lieu of a portion of his board fees. The RSUs vested upon grant and converted one-for-one into 192,308 shares of common stock at no cash exercise price, increasing his direct holdings to 743,452 shares. No RSUs from this award remain outstanding.
MariMed Inc. director Edward J. Gildea received 192,308 restricted stock units on July 15, 2026 as part of his board fees, granted in lieu of cash. These RSUs vested immediately and converted one-for-one into 192,308 common shares at no cash cost, increasing his direct holdings to 1,172,516 shares and leaving no RSUs outstanding from this award.